Aarti Pharmalabs Ltd

AI
Aarti Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Aarti Pharmalabs Ltd

₹ 873 -5.92%
30 Oct - close price
aartipharmalabs.com BSE: 543748 NSE: AARTIPHARM
About

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

Key Points

Business Overview:[1]
Aarti Pharmalabs Ltd, formerly
known as Aarti Organics, was a Wholly
Owned Subsidiary of Aarti Industries
Limited. It got demerged in Oct'22 into
a separately listed entity. Currently, the company is an internationally recognized manufacturer of generic API & Intermediates, Xanthine derivatives, and offers CDMO /CMO services. The company has 6 manufacturing plants and 3 R&D centres.

Website BSE NSE
  • Market Cap ₹ 7,914 Cr.
  • Current Price ₹ 873
  • High / Low ₹ 1,002 / 584
  • Stock P/E 32.1
  • Book Value ₹ 232
  • Dividend Yield 0.40 %
  • ROCE 11.4 %
  • ROE 9.32 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is expected to give good quarter

Cons

  • Promoter holding has decreased over last quarter: -3.20%
  • Company has a low return on equity of 12.3% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty Microcap 250 Nifty Total Market BSE 1000 BSE Healthcare Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
356 373 415 393 377 471 530 375 417 425 580 535 613
282 285 307 310 293 356 386 280 343 322 463 398 476
Operating Profit 74 88 107 84 85 115 143 95 74 103 117 136 136
OPM % 21% 24% 26% 21% 22% 24% 27% 25% 18% 24% 20% 25% 22%
0 0 6 2 3 12 -3 2 3 -3 11 3 -2
Interest 4 4 4 4 5 10 6 7 11 13 17 13 15
Depreciation 16 17 17 18 19 21 21 23 25 29 28 30 31
Profit before tax 54 67 91 63 63 96 114 67 42 59 83 96 89
Tax % 22% 29% 31% 25% 25% 24% 22% 24% 26% 25% 25% 26% 26%
42 48 63 47 48 74 89 51 31 44 62 71 66
EPS in Rs 4.61 5.32 6.95 5.20 5.28 8.11 9.80 5.65 3.41 4.84 6.84 7.86 7.25
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
0 0 941 1,511 1,502 1,771 1,798 2,152
0 0 761 1,203 1,156 1,343 1,425 1,660
Operating Profit -0 0 180 308 346 428 373 493
OPM % 19% 20% 23% 24% 21% 23%
0 0 3 1 11 13 13 9
Interest 0 0 11 20 17 26 47 57
Depreciation 0 0 37 56 66 79 104 117
Profit before tax -0 0 134 233 275 336 234 327
Tax % 0% 20% 26% 27% 23% 25%
-0 0 107 172 201 257 176 243
EPS in Rs 18.95 22.14 28.39 19.44 26.79
Dividend Payout % 0% 0% 11% 14% 18% 18%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 6%
TTM: 20%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 1%
TTM: 1%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 31%
1 Year: 2%
Return on Equity
10 Years: %
5 Years: 13%
3 Years: 12%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 0.25 0.25 0.25 45 45 45 45 45
Reserves -0 -0 1,284 1,393 1,576 1,799 1,937 2,058
0 0 327 208 272 411 754 897
0 0 215 330 404 464 591 666
Total Liabilities 0 0 1,827 1,976 2,297 2,720 3,328 3,666
0 0 701 848 953 1,059 1,437 1,604
CWIP 0 0 187 102 137 369 393 308
Investments 0 0 40 55 62 57 44 43
0 0 898 971 1,145 1,235 1,453 1,710
Total Assets 0 0 1,827 1,976 2,297 2,720 3,328 3,666

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-0 0 -65 216 184 339 257
0 0 -134 -116 -184 -418 -425
0 0 255 -157 4 79 171
Net Cash Flow 0 0 56 -56 4 -1 3
Free Cash Flow -0 0 -201 99 -5 -95 -191
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 100% -28% 88% 67% 93% 82%

Ratios

Standalone / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 118 90 109 114 119
Inventory Days 359 240 283 239 283
Days Payable 106 95 124 109 144
Cash Conversion Cycle 371 235 268 243 258
Working Capital Days 137 118 135 118 94
ROCE % 0% 18% 16% 16% 17% 11%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025 Mar 2026
APIs Commercialized (Cumulative)
count

Log in to view insights

Please log in to see hidden values.

Login
CDMO Active Customers
count
CDMO Total Active Projects (Commercial + Development)
count
CEP Approvals (Cumulative)
count
US DMF Approvals (Cumulative)
count
Xanthine Installed Capacity
MTPA
Multipurpose Reactor Capacity (API + CDMO)
kL
R&D Spend as % of API+Int & CDMO sales
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

25 Recently
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
46.46% 46.46% 46.46% 46.10% 44.65% 44.29% 43.72% 42.88% 43.10% 43.08% 42.86% 39.66%
8.17% 8.33% 7.07% 7.38% 8.64% 7.36% 7.34% 8.02% 7.69% 8.39% 8.17% 8.16%
9.91% 9.97% 11.47% 11.35% 10.36% 7.53% 7.80% 6.95% 7.66% 7.40% 7.22% 8.40%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
35.45% 35.24% 35.00% 35.17% 36.33% 40.81% 41.12% 42.12% 41.54% 41.10% 41.74% 43.78%
No. of Shareholders 2,15,7962,04,1221,89,0121,85,4361,85,1111,96,3141,87,0391,90,6551,84,4891,79,3731,76,5061,74,329

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls